Sante Health Ventures
Venture capitalActively deployingAustin
Fund manager profile
Sante Health Ventures is a venture fund manager based in Austin. SEC filings show 5 venture funds on record, most recently Sante Health Ventures V, LP ($300M offering) filed May 2025.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 5 of 6 portfolio companiesBiotech ×4Healthtech ×2AI & Machine Learning ×1Digital Health ×1
HQs:United States×6
Investments · 6 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 12022 · 12015 · 22014 · 16 dated
BiotechCleveland, US
Howard Dittrich(Executive Officer)Robert Baltera, Jr.(Executive Officer, Director)Rajesh Khosla(Executive Officer, Director)Jim Graham(Director)Arthur Brown(Executive Officer, Director)
Board seatKevin Lalande· per SEC Form D · $31.9M raise · filed Feb 2015
Co-investorsFrazier Life Sciences
Austin, US
Board seatJoe CunninghamKevin Lalande· per SEC Form D · $30M raise · filed Oct 2022
HealthtechAustin, US
Michael Gonzales(Executive Officer, Director)Barry Fromberg(Executive Officer, Director)
BoardEvan Melrose(Director)Lew Little(Director)
Board seatKevin Lalande· per SEC Form D · $8.4M raise · filed Apr 2015
Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.
BiotechHealthtechAustin, US
Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)Pisit "Duke" Pitukcheewanont(Chief Medical Officer)Lori Lawley(Chief Financial Officer)Brad Powers(Chief Compliance Officer and General Counsel)Campbell Murray(Executive Chairman)
Board seatKevin M. Lalande· per SEC Form D · $13M raise · filed May 2015
Co-investorsNew Enterprise Associates (NEA)
BiotechAustin, US
Eric E. Poma(Executive Officer, Director)Jason S. Kim(Executive Officer)David R. Hoffmann(Director)David Hirsch(Director)David Valacer(Executive Officer)Harold Selick(Director)
Board seatKevin LalandeKevin M. Lalande· per SEC Form D · $90.7M raise · filed Jul 2023
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inRichard Simon(Director)
Board seatKevin Lalande· per SEC Form D · $58.5M raise · filed Jul 2025
Co-investorsBonaventure Equity, LLCHatteras Venture PartnersIter InvestmentsMission BiocapitalRoute 66 VenturesService Provider Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesSensorium Therapeutics · finsmes.com · Aug 29, 2025
Fund performance · per public LP disclosures · 2
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Sante Health Ventures IVLPs: Pennsylvania Public School Employees' Retirement System | 2021 | — | 20.2% | 1.51x | — |
| Sante Health Ventures IIILPs: Pennsylvania Public School Employees' Retirement System | 2018 | — | 21.1% | 2.07x | 0.56x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is Sante Health Ventures located?
- Sante Health Ventures is headquartered in Austin, US.